{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-034768","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.034447+00:00","generated_at":"2026-06-26T22:00:01.664454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress","bullets":["FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.","FMX114 Phase 1b showed acceptable safety/PK; Phase 2a top-line results expected Q2 2022.","VYN201 preclinical data in TH17, fibrosis, vitiligo models show significant improvement; IND/H2 2022.","Divested MST franchise to Journey Medical for $20M upfront + $5M in 1 yr + up to $450M milestones.","Prepaid $35M debt in Aug 2021; entered $30M equity purchase agreement with Lincoln Park Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-034768","json":"https://secwatch.observer/filing/0001104659-22-034768.json","markdown":"https://secwatch.observer/filing/0001104659-22-034768.md","text":"https://secwatch.observer/filing/0001104659-22-034768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/0001104659-22-034768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/tm228420d5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:00:01.664454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}